

Additional data file 2. Clinicopathological characteristics of ovarian cancer patients (“INNSBRUCK”) for which *HOTAIR* expression and DNAm has been done (n=134).

Patients are stratified into patients who did not receive Carboplatin (16 did not receive chemotherapy and 55 received Cisplatin/Cyclophosphamide based chemotherapy) and who did receive Carboplatin-based chemotherapy (34 single agent and 29 in combination with Paclitaxel)

Characteristics	n	Chemotherapy treatment		P
		no Carboplatin (n = 71)	Carboplatin (n = 63)	
Age				
≤ 62.7 yrs. (median age)	67	40	27	0.119
> 62.7 yrs. (median age)	67	31	36	
FIGO				
I/II	37	23	14	0.189
III/IV	97	48	49	
Tumor grade				
I/II	78	46	32	0.134
III	51	24	27	
Unknown	5	1	4	
Histology				
serous cancer	56	36	20	0.210
mucinous cancer	43	22	21	
endometrioid cancer	24	8	16	
clear cell cancer	6	3	3	
Other	2	1	1	
Fallopian tube cancer	3	1	2	
Residual disease after surgery				
no residual disease	46	29	17	0.351
residual disease ≤ 2cm	36	16	20	
residual disease > 2cm	45	22	23	
Unknown	7	4	3	
<i>HOTAIR</i> expression				
Yes	72	37	35	0.731
No	62	34	28	
Health status*				
no relapse	56	31	25	0.641

Relapse	78	40	38	
Survival status*				
Alive	39	22	17	0.611
Dead	95	49	46	

Note: The significance level (P) was determined by Chi square test.
* for the entire follow up period.